Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD

BACKGROUND AND OBJECTIVES: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is commonly prescribed to patients with type 2 diabetes. As this drug is primarily eliminated by the kidney, a reduced dose is recommended for patients with CKD. Some evidence suggests that sitagliptin is associated with a h...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin J Am Soc Nephrol
Main Authors: Muanda, Flory T., Weir, Matthew A., Bathini, Lavanya, Clemens, Kristin K., Perkovic, Vlado, Sood, Manish M., McArthur, Eric, Sontrop, Jessica M., Kim, Richard B., Garg, Amit X.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Nephrology 2020
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7769019/
https://ncbi.nlm.nih.gov/pubmed/33239410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.08310520
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki